|Bid||2.0800 x 2200|
|Ask||2.0900 x 3200|
|Day's Range||2.0500 - 2.2200|
|52 Week Range||1.1300 - 4.3800|
|Beta (5Y Monthly)||-1.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.